Kalaris Therapeutics KLRS
Kalaris Therapeutics reports $11.03 million net loss
Kalaris Therapeutics (KLRS) filed a 10-Q with the SEC on Nov 10, 2026, 4:01 pm ET. Source: the filing on SEC EDGAR.
Quarterly report, 5 new risk factors
- Form
- 10-Q
- Filed
- Importance
- Notable
- Accession
- 0001193125-26-455378
- Net loss of $11.03 million for the three months ended Sep 30, 2026
- Diluted EPS of -$0.46 for the three months ended Sep 30, 2026
- Cash and equivalents of $47.38 million as of Sep 30, 2026
Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.
What changed since last quarter
5 new risk factors · 4 removed
Compared with the 10-Q for the period ended Jun 30, 2026.
| This filing | Previous | Change vs prior 10-Q | |
|---|---|---|---|
| Operating income and margin | −$11.81M | −$12.39M | +4.6% |
| Net income | −$11.03M | −$11.52M | +4.2% |
| Operating cash flow | −$10.56M | −$11.05M | +4.4% |
| Cash | $47.38M | $43.17M | +9.8% |
New risk factors (5)
- Medicare and Medicaid, imprisonment and the curtailment or restructuring of its operations, any of which could adversely affect our business, financial condition, results of operations and prospects.
- At the same time, the United States federal and state governments continue to pursue legislative and regulatory initiatives designed to reduce prescription drug spending, including the Medicare Drug Price Negotiation Program, Medicare inflation rebate requirements, and demonstration programs administered by, CMS… +2 more paragraphs
- 2025 (the "DUAA"), was approved, implementing various measures concerning data usage in the UK and reforming data protection laws. Certain provisions of the DUAA became effective in 2026, while others are expected to take effect at a later time. It remains too soon to tell how the DUAA will have an impact on our…
- Then, on April 2, 2026, President Trump issued a Proclamation invoking Section 232 of the Trade Expansion Act of 1962 to impose tariffs on imports of patented pharmaceuticals, biologics, and associated ingredients into the United States (the "Section 232 tariffs"). The action affects pharmaceutical manufacturers…
- • not being required to furnish a stock performance graph in our Annual Report on Form 10-K.
Removed risk factors (4)
- USPTO, but this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. The term of a U.S. patent may also be shortened if the patent is terminally disclaimed over an earlier-filed patent.
- Separately, on December 23, 2025, CMS, through its Center for Medicare and Medicaid Innovation, proposed two five-year pilot programs to implement a "reference pricing" regime for drugs paid for under Medicare for 25% of covered beneficiaries. The programs are referred to as the Global Benchmark for Efficient Drug…
- In addition to the provisions in certain international laws restricting the transfer of personal information to the United
- Then, on April 2, 2026, President Trump issued a Proclamation invoking Section 232 of the Trade Expansion Act of 1962 to impose tariffs on imports of patented pharmaceuticals, biologics, and associated ingredients into the United States (the "Section 232 tariffs"). The action affects pharmaceutical manufacturers…